Polaryx Therapeutics, Inc. Common Stock (PLYX) is a publicly traded the market company. As of May 21, 2026, PLYX trades at $3.42 with a market cap of $130.67M and a P/E ratio of 0.00. PLYX moved +11.11% today. Year to date, PLYX is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $2.20 to $48.91. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces PLYX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Polaryx Wins Two 2026 US Awards, Eyes H2 2026 SOTERIA Phase 2 Launch: Polaryx Therapeutics won Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative Disease Drug Development Excellence Awards in 2026. Its lead oral small-molecule candidate PLX-200 is set to enter the SOTERIA Phase 2 basket trial evaluating multiple lysosomal storage disorder indications in the second half of 2026.
| Metric | Value |
|---|---|
| Price | $3.42 |
| Market Cap | $130.67M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $48.91 |
| 52-Week Low | $2.20 |
| Volume | 239 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover PLYX: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.